JP6806679B2 - サーチュイン調節因子としての置換架橋尿素類似体 - Google Patents

サーチュイン調節因子としての置換架橋尿素類似体 Download PDF

Info

Publication number
JP6806679B2
JP6806679B2 JP2017526852A JP2017526852A JP6806679B2 JP 6806679 B2 JP6806679 B2 JP 6806679B2 JP 2017526852 A JP2017526852 A JP 2017526852A JP 2017526852 A JP2017526852 A JP 2017526852A JP 6806679 B2 JP6806679 B2 JP 6806679B2
Authority
JP
Japan
Prior art keywords
branched
sirtuin
heteroaryl
linear
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017526852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534662A5 (OSRAM
JP2017534662A (ja
Inventor
ジェームズ、ラモンド、エリス
カレン、アンダーソン、エバンス
ライアン、マイケル、フォックス
ウィリアム、ヘンリー、ミラー
マーク、アンドリュー、シーフェルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2017534662A publication Critical patent/JP2017534662A/ja
Publication of JP2017534662A5 publication Critical patent/JP2017534662A5/ja
Application granted granted Critical
Publication of JP6806679B2 publication Critical patent/JP6806679B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017526852A 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体 Expired - Fee Related JP6806679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
US62/081,916 2014-11-19
PCT/IB2015/058978 WO2016079710A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (3)

Publication Number Publication Date
JP2017534662A JP2017534662A (ja) 2017-11-24
JP2017534662A5 JP2017534662A5 (OSRAM) 2019-01-10
JP6806679B2 true JP6806679B2 (ja) 2021-01-06

Family

ID=54705247

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017526852A Expired - Fee Related JP6806679B2 (ja) 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体
JP2017526950A Pending JP2017534664A (ja) 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体
JP2017526965A Pending JP2017534665A (ja) 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体
JP2017526875A Withdrawn JP2017534663A (ja) 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017526950A Pending JP2017534664A (ja) 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体
JP2017526965A Pending JP2017534665A (ja) 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体
JP2017526875A Withdrawn JP2017534663A (ja) 2014-11-19 2015-11-19 サーチュイン調節因子としての置換架橋尿素類似体

Country Status (21)

Country Link
US (4) US20190048016A1 (OSRAM)
EP (4) EP3221317B1 (OSRAM)
JP (4) JP6806679B2 (OSRAM)
KR (4) KR20170087907A (OSRAM)
CN (4) CN107207521A (OSRAM)
AU (4) AU2015348944A1 (OSRAM)
BR (4) BR112017010599A2 (OSRAM)
CA (4) CA2968032A1 (OSRAM)
CL (1) CL2017001275A1 (OSRAM)
CO (1) CO2017004994A2 (OSRAM)
CR (1) CR20170209A (OSRAM)
DO (1) DOP2017000123A (OSRAM)
EA (1) EA201791074A1 (OSRAM)
ES (1) ES2823748T3 (OSRAM)
IL (1) IL252252A0 (OSRAM)
MX (1) MX2017006658A (OSRAM)
PE (1) PE20171257A1 (OSRAM)
PH (1) PH12017500913A1 (OSRAM)
RU (3) RU2017120858A (OSRAM)
SG (1) SG11201703824QA (OSRAM)
WO (4) WO2016079710A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653782B2 (en) 2014-11-25 2020-05-19 Nortwestern University Retroviral particles expressing Sirt1 embedded within PPCN
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
US12108665B2 (en) 2019-09-02 2024-10-01 Merck Kgaa Materials for organic electroluminescent devices
AU2020386871A1 (en) * 2019-11-19 2022-06-30 Lupin Limited Process for preparing chroman compounds
AU2021207775B2 (en) * 2020-01-17 2025-12-11 Lupin Limited Methods, processes and intermediates for preparing chroman compounds
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
WO2011059839A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
JP2015504868A (ja) * 2011-12-12 2015-02-16 エスエムビー・イノベーション・アンパルトセルスカブＳＭＢ Ｉｎｎｏｖａｔｉｏｎ ＡｐＳ サーチュイン結合および調節に有用な新規複素環化合物
BR112015028613A2 (pt) * 2013-05-13 2017-07-25 Glaxosmithkline Llc análogos de uréia com ligações por pontes substituída como moduladores de sirtuína

Also Published As

Publication number Publication date
US20170355705A1 (en) 2017-12-14
BR112017010602A2 (pt) 2017-12-26
CA2968030A1 (en) 2016-05-26
RU2017120857A (ru) 2018-12-19
AU2015348942A1 (en) 2017-06-01
BR112017010595A2 (pt) 2018-01-02
PE20171257A1 (es) 2017-08-28
AU2015348943A1 (en) 2017-06-01
RU2017120858A (ru) 2018-12-19
KR20170083133A (ko) 2017-07-17
CA2968027A1 (en) 2016-05-26
EP3220918A1 (en) 2017-09-27
EP3221316A1 (en) 2017-09-27
AU2015348941A1 (en) 2017-06-01
IL252252A0 (en) 2017-07-31
AU2015348942B2 (en) 2018-07-05
CN107207521A (zh) 2017-09-26
PH12017500913A1 (en) 2017-12-04
CO2017004994A2 (es) 2017-09-20
US20170362234A1 (en) 2017-12-21
JP2017534664A (ja) 2017-11-24
KR20170083135A (ko) 2017-07-17
CL2017001275A1 (es) 2017-12-15
CN107108627A (zh) 2017-08-29
CN107207520A (zh) 2017-09-26
EA201791074A1 (ru) 2017-10-31
CR20170209A (es) 2017-07-17
AU2015348944A1 (en) 2017-06-01
CA2968029A1 (en) 2016-05-26
US20190048016A1 (en) 2019-02-14
RU2017120855A (ru) 2018-12-19
SG11201703824QA (en) 2017-06-29
EP3221322A1 (en) 2017-09-27
JP2017534663A (ja) 2017-11-24
EP3221317A1 (en) 2017-09-27
MX2017006658A (es) 2018-01-15
CA2968032A1 (en) 2016-05-26
EP3221317B1 (en) 2020-07-22
CN107207509B (zh) 2020-04-21
BR112017010599A2 (pt) 2017-12-26
WO2016079709A1 (en) 2016-05-26
WO2016079712A1 (en) 2016-05-26
JP2017534665A (ja) 2017-11-24
KR20170087907A (ko) 2017-07-31
US10072011B2 (en) 2018-09-11
ES2823748T3 (es) 2021-05-10
WO2016079711A1 (en) 2016-05-26
BR112017010601A2 (pt) 2017-12-26
DOP2017000123A (es) 2017-08-15
CN107207509A (zh) 2017-09-26
JP2017534662A (ja) 2017-11-24
WO2016079710A1 (en) 2016-05-26
KR20170083134A (ko) 2017-07-17
US20180319810A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
JP6806679B2 (ja) サーチュイン調節因子としての置換架橋尿素類似体
JP6833686B2 (ja) サーチュイン調節剤としての置換架橋尿素類似体
KR20120092141A (ko) 시르투인 조절제로서의 비시클릭 피리딘 및 유사체
TW202104223A (zh) 磷脂醯肌醇3-激酶抑制劑
JP2014530869A (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
WO2016081692A2 (en) Substituted bridged urea analogs as sirtuin modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201204

R150 Certificate of patent or registration of utility model

Ref document number: 6806679

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees